<DOC>
	<DOCNO>NCT02355106</DOCNO>
	<brief_summary>The objective study demonstrate safety feasibility Adagio System subject Atrial Flutter .</brief_summary>
	<brief_title>Prospective , Multicenter , Investigation Adagio System Subjects With Atrial Flutter</brief_title>
	<detailed_description />
	<mesh_term>Atrial Flutter</mesh_term>
	<criteria>Two symptomatic episode typical AFl ( chronic atrial flutter ) oneyear period prior enrollment . This may include typical AFl occur receive antiarrhythmic drug ( AAD ) therapy nonAFl tachyarrhythmia , include atrial fibrillation ( AF ) . At least one episode typical ( clockwise counterclockwise ) atrial flutter document 12 lead electrocardiogram ( ECG ) within 6 month prior enrollment . Subject diagnose symptomatic AFl Subject least 18 ≤75 year age . Subject able willing give inform consent Intracardiac thrombus eliminate subject expose less 4 week therapeutic anticoagulation TEE ( transesophageal echocardiogram ) and/or CT conclusively rule thrombus Subject develop persistent AF least history ( electrical pharmacological cardioversion 48h episode duration &gt; 7 day ) . Subject previous leave atrial ablation . Subject previous cardiac surgery , e.g . prosthetic valve , except case isolate coronary bypass surgery perform three month prior procedure . Subject permanent pacemaker defibrillator implant . Subject 2° type II , 3° degree atrioventricular ( AV ) block left/right bundle branch block pattern Subject unstable angina pectoris . Subject history previous myocardial infarction ( MI ) percutaneous intervention last three month plan next 3 month . Subject symptomatic carotid stenosis . Subject chronic obstructive pulmonary disease detect pulmonary hypertension evidence significant lung disease . Subject contraindication oral anticoagulation . Subject history previous transient ischemic attack ( TIA ) stroke . Subject know intracardiac thrombus formation . Subject significant congenital heart defect correct ( except patent foramen ovale allow ) . Subject evidence congestive heart failure ( NYHA class II , III IV ) sinus rhythm . Subject hypertrophic cardiomyopathy . Subject abnormal long short QT interval , sign Brugada syndrome , know inherit ion channel disease family , arrhythmogenic right ventricular dysplasia . Subject sarcoidosis . Subject myxoma . Subject thrombocytosis ( platelet count &gt; 600,000 / μl ) thrombocytopenia ( platelet count &lt; 100,000 / μl ) . Subject untreated uncontrolled hyperthyroidism hypothyroidism . Subject renal dysfunction glomerular filtration rate &lt; 60 ml/min/1.72m2 . Subject reversible cause AF like alcoholism . Subject pregnant woman woman childbearing potential adequate birth control : woman highly effective method contraception [ oral contraception intrauterine device ] ( must negative pregnancy test within 1 week randomization ) sterile woman enrol . Subject breastfeed woman . Subject active systemic infection . Subject unwilling unable comply fully study procedure followup due disease condition , raise doubt compliance influence study outcome especially kind cancer require ongoing inhospital treatment , severe bleed history suspect procoagulant state . Legal incapacity evidence subject understand purpose risk study inability comply fully study procedure follow . Subject life expectancy ≤ 1 year . Subject participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>